The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of knownCYP2C19Genotype

Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1

(2013) Christoph Markert et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review

(2013) J.C. Stingl et al.   PHARMACOLOGY & THERAPEUTICS

Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity

(2012) Ines Fuchs et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

(2011) T Simon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

(2011) S Katzenmaier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring

(2011) Arwa Hassan et al.   THERAPEUTIC DRUG MONITORING

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.

(2010) J. Craig Hartman et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects

(2010) Brooke Harrison et al.   CLINICAL DRUG INVESTIGATION

Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

(2010) R Spence et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status

(2010) D. H. McCollister et al.   PSYCHOSOMATICS

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

(2009) Alain Li-Wan-Po et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

(2009) V Hafner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan

(2009) Duncan B. Richards et al.   JOURNAL OF CLINICAL PHARMACOLOGY

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers

(2009) Rebecca Spence et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Ambrisentan

(2008) Jamie D Croxtall et al.   DRUGS

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

(2008) I. Rudberg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

(2008) Rebecca Spence et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

(2008) N Galiè et al.   LANCET